Status:
RECRUITING
A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy
Lead Sponsor:
Peking University Cancer Hospital & Institute
Conditions:
MSS Metastatic Colorectal Cancers
MSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
Eligibility:
All Genders
18+ years
Brief Summary
This study is a single-center prospective exploratory research, aiming to identify clinical characteristics and biomarkers associated with the therapeutic effects of dual PD1/PDL1 and CTLA4 blockade p...
Detailed Description
This study is a single-center prospective exploratory research. Patients with MSS metastatic colorectal cancer and MSI solid tumors resistant to PD-1/PD-L1 antibody monotherapy who are treated with du...
Eligibility Criteria
Inclusion
- Pathologically confirmed MSS metastatic colorectal cancers or MSI solid tumors refractory to PD1/PDL1 antibody monotherapy
- Receiving dual blockade of PD1/PDL1 and CTLA4 in combination of anti-angiogenic treatment with or without other therapies
Exclusion
- ●Having malignancies in non-gastrointestinal system that have not been cured (Lynch syndrome not included)
Key Trial Info
Start Date :
January 10 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2028
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06549907
Start Date
January 10 2024
End Date
September 30 2028
Last Update
August 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jian Li
Beijing, Beijing Municipality, China, 100142